title: NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors.
abstract: Aurora A kinase (AURKA) is overexpressed in 96% of human cancers and is considered an independent marker of poor prognosis. While the majority of tumors have elevated levels of AURKA protein, few have AURKA gene amplification, implying that posttranscriptional mechanisms regulating AURKA protein levels are significant. Here, we show that NEDD9, a known activator of AURKA, is directly involved in AURKA stability. Analysis of a comprehensive breast cancer tissue microarray revealed a tight correlation between the expression of both proteins, significantly corresponding with increased prognostic value. A decrease in AURKA, concomitant with increased ubiquitination and proteasome-dependent degradation, occurs due to depletion or knockout of NEDD9. Reexpression of wild-type NEDD9 was sufficient to rescue the observed phenomenon. Binding of NEDD9 to AURKA is critical for AURKA stabilization, as mutation of S296E was sufficient to disrupt binding and led to reduced AURKA protein levels. NEDD9 confers AURKA stability by limiting the binding of the cdh1-substrate recognition subunit of APC/C ubiquitin ligase to AURKA. Depletion of NEDD9 in tumor cells increases sensitivity to AURKA inhibitors. Combination therapy with NEDD9 short hairpin RNAs and AURKA inhibitors impairs tumor growth and distant metastasis in mice harboring xenografts of breast tumors. Collectively, our findings provide rationale for the use of AURKA inhibitors in treatment of metastatic tumors and predict the sensitivity of the patients to AURKA inhibitors based on NEDD9 expression.
authors.affiliation: Department of Biochemistry, West Virginia University School of Medicine, Morgantown, WV 26506, USA
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Ice
authors.forename: Sarah L
authors.initials: SL
authors.lastname: McLaughlin
authors.forename: Ryan H
authors.initials: RH
authors.lastname: Livengood
authors.forename: Mark V
authors.initials: MV
authors.lastname: Culp
authors.forename: Erik R
authors.initials: ER
authors.lastname: Eddy
authors.forename: Alexey V
authors.initials: AV
authors.lastname: Ivanov
authors.forename: Elena N
authors.initials: EN
authors.lastname: Pugacheva
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000037:antagonists & inhibitors / Q000502:physiology*; D000818:Animals; D064096:Aurora Kinase A; D064127:Aurora Kinases; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004795:Enzyme Stability; D005260:Female; D006801:Humans; D051379:Mice; D009362:Neoplasm Metastasis; D010750:Phosphoproteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D046988:Proteasome Endopeptidase Complex / Q000502:physiology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D004791:Enzyme Inhibitors; C099942:NEDD9 protein, human; D010750:Phosphoproteins; C576917:AURKA protein, human; C576918:Aurka protein, mouse; D064096:Aurora Kinase A; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases; D046988:Proteasome Endopeptidase Complex
references.citation: Oncogene. 1997 May 8;14(18):2195-200
references.pmid: 9174055
references.citation: J Cell Sci. 2012 Mar 1;125(Pt 5):1204-16
references.pmid: 22492986
references.citation: Clin Cancer Res. 2006 Jul 1;12(13):4080-9
references.pmid: 16818708
references.citation: J Cell Sci. 2004 Dec 1;117(Pt 25):5975-83
references.pmid: 15536123
references.citation: Curr Opin Cell Biol. 1999 Dec;11(6):708-16
references.pmid: 10600711
references.citation: Nat Cell Biol. 2003 Mar;5(3):242-8
references.pmid: 12577065
references.citation: Cell. 2003 Sep 5;114(5):585-98
references.pmid: 13678582
references.citation: J Cell Sci. 2006 Jan 1;119(Pt 1):96-103
references.pmid: 16352661
references.citation: Cell Cycle. 2006 Feb;5(4):384-91
references.pmid: 16479169
references.citation: Curr Biol. 2008 Nov 11;18(21):1649-58
references.pmid: 18976910
references.citation: Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6740-5
references.pmid: 17420468
references.citation: Clin Cancer Res. 2011 Dec 15;17(24):7614-24
references.pmid: 22016509
references.citation: Curr Opin Genet Dev. 2000 Feb;10(1):54-64
references.pmid: 10679394
references.citation: Nature. 2005 Jul 28;436(7050):518-24
references.pmid: 16049480
references.citation: Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68
references.pmid: 18089710
references.citation: J Biol Chem. 2011 Nov 11;286(45):38960-8
references.pmid: 21890637
references.citation: Cancer Res. 2009 Jun 1;69(11):4555-8
references.pmid: 19487276
references.citation: BMC Cell Biol. 2004 May 16;5:20
references.pmid: 15144564
references.citation: FEBS Lett. 2002 May 22;519(1-3):59-65
references.pmid: 12023018
references.citation: Cell. 2007 Jun 29;129(7):1351-63
references.pmid: 17604723
references.citation: Methods. 2013 Jan;59(1):32-46
references.pmid: 22975077
references.citation: Mol Cell Biol. 2007 Jun;27(12):4513-25
references.pmid: 17438137
references.citation: Cancer Res. 1999 May 1;59(9):2041-4
references.pmid: 10232583
references.citation: Exp Ther Med. 2012 Jul;4(1):33-42
references.pmid: 23060919
references.citation: Pediatr Blood Cancer. 2010 Jul 15;55(1):26-34
references.pmid: 20108338
references.citation: Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54
references.pmid: 20607239
references.citation: J Cell Sci. 2011 Jan 1;124(Pt 1):113-22
references.pmid: 21147853
references.citation: Nat Cell Biol. 2005 Oct;7(10):937-46
references.pmid: 16184168
references.citation: Nat Genet. 1998 Oct;20(2):189-93
references.pmid: 9771714
references.citation: Ann Oncol. 2007 Jun;18 Suppl 6:vi47-52
references.pmid: 17591831
references.citation: Chromosoma. 2008 Oct;117(5):457-69
references.pmid: 18521620
references.citation: Cell. 2006 Jun 30;125(7):1269-81
references.pmid: 16814714
references.citation: EMBO J. 1998 Jun 1;17(11):3052-65
references.pmid: 9606188
references.citation: PLoS One. 2011 May 11;6(5):e19718
references.pmid: 21589936
references.citation: Dev Cell. 2006 Aug;11(2):147-57
references.pmid: 16890155
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4455-62
references.pmid: 18628459
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11
references.pmid: 17360485